Previous 10 | Next 10 |
Artystarty/iStock via Getty Images Thanks to the prospects of earning a spot in the S&P 500 Index, Moderna (MRNA) jumped ~23.0% this week to breeze past $100B market capitalization. The frontrunner in COVID-19 vaccine development has taken less than three yea...
MediaCo (MDIA) +312%.State Auto Financial (STFC) +191%.SGOCO (SGOC) +104%.SCWorx (WORX) +59%.Tempest (TPST) +54%.Origin Agritech (SEED) +41%.Datasea (DTSS) +39%.Creatd (CRTD) +33%.Cemtrex (CETX) +32%.Ayala Pharmaceuticals (AYLA) +29%.Celldex Therapeutics (CLDX) +25%.Baosheng Media (BAOS) +25%...
REHOVOT, Israel & WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announ...
- First Patient Dosed in Phase 1 AL102 Combination Trial with Novartis’ Anti-BCMA Agent for the Treatment of Multiple Myeloma - - On Track to Initiate AL102 Phase 2/3 Pivotal Trial for the Treatment of Desmoid Tumors in 1H21- - Multiple Near-Term Milestones Expect...
REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announc...
The FDA approval process for vaccines, therapeutics, and other pharmaceuticals was on the nightly news through late 2020. Investors and non-investors alike developed some understanding of that FDA timeline. Medical device clearance is less understood yet critical for investors looking to benef...
Ayala Pharmaceuticals (AYLA): FY GAAP EPS of -$3.06 misses by $0.84.Revenue of $3.71M (+59.2% Y/Y) beats by $1.53M.Press Release For further details see: Ayala Pharmaceuticals EPS misses by $0.84, beats on revenue
- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023 - Accelerated Development of AL102 Desmoid Tumor Program into Phase 2/3 Pivotal Trial - On Track to Report Multiple Milestones in 2021 Across Clinical-Stage Pipeline REHOVOT, Israel and WI...
The following slide deck was published by Ayala Pharmaceuticals, Inc. in conjunction with this event. For further details see: Ayala Pharmaceuticals (AYLA) Investor Presentation - Slideshow
Ayala Pharmaceuticals ([[AYLA]] +5.0%) entered into a definitive agreement for the sale of its equity securities in a private placement to institutional investors, including Redmile Group and SIO Capital Management.Ayala plans to sell 1.67M units at $15/unit; each unit consists of one share a...
News, Short Squeeze, Breakout and More Instantly...
Ayala Pharmaceuticals Inc. Company Name:
AYLA Stock Symbol:
NASDAQ Market:
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Societ...
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmace...